A Giebler, R Sniecinski - Current Anesthesiology Reports, 2024 - Springer
Direct Oral Anticoagulants: An Update on Monitoring and Antidotes for the Perioperative Physician | Current Anesthesiology Reports Skip to main content SpringerLink Account …
Direct oral anticoagulants (DOACs) describe a group of drugs that have emerged over the last decade, which are active against either activated factor II (or thrombin; IIa) or activated …
RC Gosselin, A Cuker - Clinics in Laboratory Medicine, 2024 - labmed.theclinics.com
Assessing Direct Oral Anticoagulants in the Clinical Laboratory - Clinics in Laboratory Medicine Skip to Main Content Skip to Main Menu Advertisement Clinics in Laboratory …
T Wu, S Wu, M Li, J Zhang - Annals of Pharmacotherapy, 2024 - journals.sagepub.com
Background: Rivaroxaban has predictable pharmacokinetics and pharmacodynamics. However, monitoring rivaroxaban concentrations should be provided for special patients …
R Hall, S Suarez, M Majumdar, I Lee… - Annals of Vascular …, 2024 - Elsevier
Background Metabolic comorbidities such as diabetes and obesity are considered pro- inflammatory states which theoretically increase the risk of perioperative thrombotic events …
Y Fukuda, K Yoshinaga, S Kondo, Y Iizuka, M Sanui - Cureus, 2024 - cureus.com
Andexanet alfa neutralizes factor Xa inhibitors in critical bleeding situations. However, in cardiac surgery with cardiopulmonary bypass (CPB), heparin resistance induced by …
T Gencpinar, H Dursun, C Bilen, B Kemahli… - Authorea …, 2024 - advance.sagepub.com
Background: Optimum treatment options for arterial thrombosis are antiplatelet and anticoagulant treatments. We evaluated the effectiveness of Apixaban and Rivaroxaban …